Vanguard Group’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Vanguard Group’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-378,677	Closed	-$30.7K	–	4654
2022 Q4	$30.7K	Hold	378,677	–	–	﹤0.01%	4474
2022 Q3	$49K	Sell	378,677 -10,433	-3%	-$2.2K	﹤0.01%	4548
2022 Q2	$111K	Hold	389,110	–	–	﹤0.01%	4536
2022 Q1	$122K	Sell	389,110 -28,249	-7%	-$30.2K	﹤0.01%	4583
2021 Q4	$960K	Sell	417,359 -8,982	-2%	-$26.5K	﹤0.01%	4277
2021 Q3	$984K	Buy	426,341 +328,806	+337%	+$1.25M	﹤0.01%	4249
2021 Q2	$533K	Buy	97,535 +29,443	+43%	+$159K	﹤0.01%	4260
2021 Q1	$357K	Buy	68,092 +15,500	+29%	+$84.8K	﹤0.01%	4182
2020 Q4	$181K	Hold	52,592	–	–	﹤0.01%	4099
2020 Q3	$104K	Hold	52,592	–	–	﹤0.01%	4012
2020 Q2	$135K	Hold	52,592	–	–	﹤0.01%	3963
2020 Q1	$88K	Buy	52,592 +17,639	+50%	+$36K	﹤0.01%	3959
2019 Q4	$21K	Sell	34,953 -18,132	-34%	-$13.4K	﹤0.01%	4088
2019 Q3	$54K	Buy	53,085 +211	+0.4%	+$284	﹤0.01%	4080
2019 Q2	$77K	Sell	52,874 -53,800	-50%	-$83.3K	﹤0.01%	4072
2019 Q1	$176K	Hold	106,674	–	–	﹤0.01%	3947
2018 Q4	$108K	Sell	106,674 -63,673	-37%	-$110K	﹤0.01%	3991
2018 Q3	$342K	Hold	170,347	–	–	﹤0.01%	3915
2018 Q2	$419K	Hold	170,347	–	–	﹤0.01%	3850
2018 Q1	$514K	Buy	170,347 +13,101	+8%	+$46.2K	﹤0.01%	3780
2017 Q4	$631K	Sell	157,246 -12,842	-8%	-$39K	﹤0.01%	3696
2017 Q3	$586K	Hold	170,088	–	–	﹤0.01%	3714
2017 Q2	$501K	Buy	170,088 +87,885	+107%	+$287K	﹤0.01%	3726
2017 Q1	$132K	Hold	82,203	–	–	﹤0.01%	3964
2016 Q4	$117K	Hold	82,203	–	–	﹤0.01%	3962
2016 Q3	$143K	Sell	82,203 -5,815	-7%	-$12.8K	﹤0.01%	3948
2016 Q2	$248K	Hold	88,018	–	–	﹤0.01%	3908
2016 Q1	$223K	Buy	88,018 +500	+0.6%	+$1.68K	﹤0.01%	3938
2015 Q4	$306K	Sell	87,518 -1,065	-1%	-$4.29K	﹤0.01%	3937
2015 Q3	$385K	Buy	88,583 +5,400	+6%	+$22K	﹤0.01%	3919
2015 Q2	$361K	Buy	83,183 +1,135	+1%	+$3.42K	﹤0.01%	3946
2015 Q1	$295K	Buy	82,048 +11,446	+16%	+$47K	﹤0.01%	3935
2014 Q4	$402K	Sell	70,602 -1,544	-2%	-$12.1K	﹤0.01%	3789
2014 Q3	$662K	Buy	72,146 +1,965	+3%	+$18K	﹤0.01%	3635
2014 Q2	$674K	Buy	70,181 +1,687	+2%	+$19.7K	﹤0.01%	3601
2014 Q1	$933K	Buy	68,494 +1,245	+2%	+$20.3K	﹤0.01%	3477
2013 Q4	$1.57M	Hold	67,249	–	–	﹤0.01%	3289
2013 Q3	$2.1M	Buy	67,249 +78	+0.1%	+$2.58K	﹤0.01%	3112
2013 Q2	$2.12M	Buy	+67,171	New	+$2.31M	﹤0.01%	3047

Other funds holding STAB

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Tucker Asset Management Littleton, Colorado $405M AUM 27.41% 1-Year Est. Return

Vanguard Group's STAB Position: Q1 2023 in Review

Vanguard Group sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 378,677 shares — an estimated $30.7K sold.

Vanguard Group first reported a position in STAB in Q2 2013 and held it in 39 quarters. The position peaked at $2.12M in Q2 2013. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

Vanguard Group reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Vanguard Group sold 378,677 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $30.7K.
Vanguard Group first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 39 quarters.
Vanguard Group's Statera Biopharma, Inc. Common Stock position peaked at $2.12M in Q2 2013.
4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.